The Oncologist, Vol. 12, No. 2, 186-190, February 2007; doi:10.1634/theoncologist.12-2-186 © 2007 AlphaMed Press
New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian CancerDepartment of Gynecologic Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Key Words. Ovarian cancer • Cancer chemotherapy • Combination chemotherapy • Second-line chemotherapy Correspondence: Maurie Markman, M.D., University of Texas M.D. Anderson Cancer Center (Mail Box 121), 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Telephone: 713-745-7140; Fax: 713-563-9586; e-mail: mmarkman{at}mdanderson.org
Over the past several years, clinical research efforts in ovarian cancer employing a number of U.S. Food and Drug Administration (FDA)-approved antineoplastic agents have permitted the development of approaches that both improve the effectiveness and decrease the toxicities of systemic therapy of ovarian cancer. These initiatives, including prospective trials and retrospective examinations of large clinical experience, have involved agents previously approved by the FDA for use in ovarian cancer (e.g., cisplatin, paclitaxel, topotecan, and liposomal doxorubicin) and the development of new strategies for drugs approved for other malignant conditions (e.g., gemcitabine, docetaxel, etoposide, irinotecan, vinorelbine, and bevacizumab). It can be anticipated that future studies involving novel approved agents will further expand the oncologists weapons against ovarian cancer.
This article has been cited by other articles:
Copyright © 2007 by AlphaMed Press. |
||||||||||||||||||||||||||||||||||||||||||||